Context

While antipsychotic medications are the cornerstone of treatment for schizophrenia, there is a subset of patients whose condition cannot be adequately managed with these pharmacological compounds. In other words, for this group, the core symptom domain of schizophrenia—namely, positive or psychotic symptoms—remains uncontrolled. This subset, comprising a significant portion of individuals with schizophrenia, is referred to as having treatment-resistant schizophrenia (TRS). The persistence of their symptoms despite antipsychotic treatment leads to considerable psychological and economic burdens for the patients, their …